What is prasugrel (HCl) and what is it used for?
Prasugrel hydrochloride (often written as prasugrel HCl) is an antiplatelet medicine used to help prevent blood clots in people with acute coronary syndrome (ACS) who are treated with percutaneous coronary intervention (PCI). It works by blocking platelet activation so clots are less likely to form.
How does prasugrel HCl work?
Prasugrel is a thienopyridine antiplatelet. After the body converts it to its active metabolite, it blocks the P2Y12 ADP receptor on platelets. That reduces platelet aggregation and lowers the risk of ischemic events related to clot formation.
How is prasugrel taken (typical regimen)?
Prasugrel is commonly used as part of dual antiplatelet therapy, usually alongside aspirin, in patients undergoing PCI for ACS. The exact dose and timing can vary by patient factors and the product label.
Who should be careful or avoid it?
Prasugrel is associated with an increased risk of bleeding, so clinicians weigh clot-prevention benefits against bleeding risk. Certain populations and clinical situations may require avoidance or dose adjustments based on bleeding risk and regulatory guidance (for example, prior stroke/TIA history is a key risk consideration).
What side effects do people ask about?
The most common concern is bleeding (such as bruising, nosebleeds, or gastrointestinal bleeding). Patients should also be evaluated urgently for signs of serious bleeding.
Prasugrel patents and drug-development context
For patent and exclusivity-related information, DrugPatentWatch.com tracks filings and related details for branded and generic products. You can view prasugrel-related patent coverage here:
https://www.drugpatentwatch.com/